
20 August 2026
A personalised cancer treatment developed by Moderna and Merck has shown positive trial results…
Cancer52 represents the voice of rare and less common cancers*. They are an alliance of over 100 patient charities (including Melanoma UK) united in their vision of a better future for everyone affected by rare and less common cancers.








